



GLUCOSAMINE SULPHATE TRANSDERMAL GELS: AN ALTERNATIVE ROUTE FOR DRUG DELIVERY

Alaa Mohammad Abdel Azim^{1*}

¹Department of Toxic and Narcotic Drug Forensic Medicine, Cairo, Egypt

ABSTRACT

The purpose of the present study was to develop transdermal delivery systems of Glucosamine Sulphate using thermoreversible polymer Pluronic F-127 (PF-127) and mucoadhesive polymer sodium carboxymethylcellulose (Na CMC) in order to optimize its release profile, and the overall clinical performance. Glucosamine (G) is known to be formulated in an oral dosage form, but it suffers from hepatic metabolism which greatly affects its bioavailability, in addition to its side effects on the gastrointestinal tract (GIT). Gel formulae were subjected to rheological studies, in-vitro release, and effect of 10% dimethylsulphoxide (DMSO) on rat skin permeation. Higuchi diffusion model was the best fitted model for the release results. PF127 and Na CMC gels showed high permeation results, and 25% PF-127 gel showed no skin irritation or histological change of skin layers. The results obtained suggest the feasibility of designing a successful transdermal delivery system providing constant (G) input and overcoming the disadvantages of oral administration.

Keywords: Transdermal, Glucosamine.

Correspondence to Author

Alaa Mohammad Abdel Azim

Department of Toxic and Narcotic
Drug Forensic Medicine, Cairo, Egypt

Email: prettylollaqueen@yahoo.com

INTRODUCTION

Osteoarthritis (OA), previously called degenerative joint disease, is the most common form of arthritis and is often associated with disability, functional impairment, and impaired quality of life [1-3]. A new perspective in OA management is to delay disease progression by modifying joint structure. Much attention has been focused on biological compounds, particularly glucosamine. Some evidence suggests it has both analgesic and disease-modifying effects without affecting cyclooxygenase, and so stabilize cell membrane

and increase the intracellular ground substance [4, 5].

Glucosamine (G), an amino monosaccharide, is a natural component of glycoprotein found in connective tissue and gastrointestinal mucosal membranes [6, 7]. Each person naturally produces a certain amount of glucosamine within his or her body, but the amount might not be sufficient for healthy joint maintenance, especially as age increases [8].

The compound GS can be derived from chitin. Chitin is the second most abundant polymer on

earth and is available from, for example, crab, lobster, shrimp or oyster shells. It can also be produced by synthetic means [9].

Directly or indirectly, glucosamine plays a role in the formation of articular surfaces, tendons, ligaments, synovial fluids, skin, bone, nails, heart valves, blood vessels and mucous secretion within the digestive, respiratory and urinary systems [10].

G has been evaluated as a therapeutic agent for OA in Germany since 1969 [9]. It has been used to treat OA for more than 20 years.

Approximately 70% of the oral GS is absorbed through the intestine and excreted through the renal system. The majority of clinical trials on oral glucosamine have used a standard dosage of glucosamine, 500mg taken three times daily, with or without rescue pain medication as required by the patient [11].

The benefit of GS in patients with osteoarthritis is likely the result of a number of effects including its anti-inflammatory activity [12, 13], the stimulation of the synthesis of proteoglycans [14], and the decrease in catabolic activity of chondrocytes inhibiting the synthesis of proteolytic enzymes and other substances that contribute to damage cartilage matrix and cause death of articular chondrocytes [15-18]. Recently, glucosamine has been shown to inhibit the expression of inducible nitric oxide synthase (iNOS), thereby suppressing the excess production of NO [19].

Long term use of (G) may reduce radiographic progression of OA of the knee, suggesting that it may be a chondroprotective, disease modifying agent in OA of the knee [20].

Although rapidly absorbed from the gastrointestinal tract, pharmacokinetic data show that when administered orally, G could be

subjected to uptake and degradation by the liver and uptake into non-joint tissues so that the dose reaching the articular cartilage is a fraction of a percentage of the oral dose [21, 22].

In the present study, a transdermal gels for GS were prepared using 10% dimethyl sulphoxide (DMSO), as a penetration enhancer, incorporated in PF-127 gel and Na CMC gel. in addition to In-vitro permeation across rat skin, evaluation of skin irritation and histological toxicity were studied.

MATERIALS AND METHODS

MATERIALS

GS was purchased from MP Biomedicals, Inc. (France). Ninhydrine was purchased from RFCL, Limited, (India). Na CMC, Potassium dihydrogen ortho phosphate, disodium hydrogen phosphate, Sodium hydroxide, orthophosphoric acid were purchased from El-Nasr Pharmaceutical Chemicals Co.(Adwic, Egypt). P F-127 was purchased from Sigma-Aldrich, (Germany). Methyl parben kindly supplied from GlaxoSmithKline (GSK), (Egypt). DMSO was purchased from Sd fine-chem. Limited, Mumbai, (India). Male albino adult rats. (The post conduction approval for this experimental study was attached, approval from Research Ethical Committee, Faculty of Pharmacy, Cairo University, EGYPT).

Gel preparation

Na CMC at different concentrations was sprinkled into a calculated amount of distilled water stirred using magnetic stirrer. GS 5% was dissolved in distilled water and added to the previous mixture. The poloxamer gel was prepared using the cold preparation method [23]. DMSO was added to each formula. Different gel formulations are illustrated in table (1).

Table (1): Quantitative Composition of Glucosamine Sulphate gels (%wt/wt).

Ingredients (g %)	Gel Formulae					
	F1	F2	F3	F4	F5	F6
NaCMC	5	5.5	6	-	-	-
PF-127	-	-	-	15	20	25
DMSO	10	10	10	10	10	10
dist. H ₂ O to	100	100	100	100	100	100

Rheological Measurements and Data Analysis:

A sample of the freshly prepared gel was placed in the cup of Brookfield Viscometer; using spindle 52 and temperature of 25°C. Measurements were made over the whole range of speed setting ranging from 0.1 to 250 rpm with 30 seconds between each two successive measurements.

***In-vitro* Release of Glucosamine Sulphate from different Gel Formulations:**

This study was carried out using the paddle method. Three grams of the gel containing 5% GS were spreaded over the surface of watch glass of 8 cm diameter and covered with equally sized wire screen mesh. The gel loaded watch glass and the covering screen were held together by equally spaced 3 inert plastic binder clips and placed at the bottom of dissolution vessel [24,25].

The *in-vitro* release was carried out using Sotax apparatus, release medium was 400 ml of phosphate buffer at pH 5.5, adjusted at temperature of 32 ± 0.5 °C, paddle speed was 100 rpm.

At predetermined time intervals, aliquots of the release medium were withdrawn, filtered through a Millipore filter of 0.45 µm and analyzed for GS content. Equal volumes of the buffer solution were added to the release medium to maintain the total dissolution medium constant.

Kinetic Analysis of the Drug Release:

Kinetic analysis of GS release data from the prepared gel formulae was determined by finding the best fit of the release data to distinct models (Zero order, First order and Simplified Higuchi Diffusion Model).

Release efficiency (RE), which describes the whole release profile (rate and extent of release), was calculated for each gel formula, values of RE were calculated for the maximum release time (RE 210 based on 210 minutes).

The obtained RE data of different gel formulae were analyzed using one-way analysis of variance (ANOVA), in order to detect the difference in release profile of the studied formulae, at $p \leq 0.05$ using SPSS® software.

***In-vitro* permeation studies of GS through full thickness rat skin**

A vertical diffusion cell with double open sided tube was used [26]. The donor vehicle was 3 gm medicated gel placed on the dorsal side of the excised skin of newly born albino rats. The available skin diffusion area was 6.16 cm². The receptor medium was 100 ml of phosphate buffer pH 7.4 [27-30] agitated by magnetic stirrer at 300 rpm (by the aid of 2 cm Teflon coated magnetic bar). Experiments were carried out at 37°C using water bath. Samples were withdrawn at predetermined time intervals up to 24 h and compensated immediately with fresh receptor medium. Samples were assayed spectrophotometrically at 570 nm, depending on Yunqi Wu, et al (2005) [31] method, using a Shimadzu UV Spectrophotometer (UV-1601). The data were analyzed statistically by the one-way ANOVA. This statistical analysis was carried out using SPSS® software.

***In-vitro* Skin Permeation Study After Addition of Permeation Enhancer:**

The permeation enhancer DMSO was added to the selected gel formulae to produce a concentration of 10% of the total gel weight. These formulae were subjected to skin permeation study as mentioned before.

Skin Irritation and Histological evaluation of the skin Test

The skin irritation test was carried out on male albino adult rats weighing 250 ± 10 g. The animals were kept under standard laboratory conditions, with temperature of 25 ± 1 °C and relative humidity of 45-60 %, with free access to water and food. The back of the animals was clipped free of fur with an electric clipper 24 hours before application of the sample. For the experiment, GS gel was applied to one shaved site; another site was used as control.

Both the treated and controlled sites were covered by gauze and the back of the rabbit was wrapped with a non-occlusive bandage. The application of the gel was daily, and the animals were observed for the reactions, defined as erythema and edema, and evaluated to the scoring

system for skin reactions (Table 2). "Total score" was calculated by summing up each participant's higher score between the 5 assessments (3, 7, 14, 21 and 30 days). A skin irritation index was calculated using the formula "skin irritation index = (total score) / (number of participants) × 100" based on the scores yielded by the assessment. A skin irritation index was classified according to the criteria for irritation caused by medicines for external application (table 2). In Shin Iri et al this

Table 2: Japanese criteria for patch test

Condition	Assessment	Score
No reaction	-	0
Mild erythema	±	0.5
Erythema	+	1
Erythema and edema	++	2
Erythema and edema with papular rash or vesicles	+++	3
Bulla	++++	4

RESULTS AND DISCUSSION


Rheological Measurements and Data Analysis:

Visual inspection revealed clear translucent gels. The exhibited non-Newtonian thixotropic,


classification, a safe, acceptable, and mildly irritating product was defined as a skin irritation index of 5.0 or lower, 15.0 or lower, and above 15.0, respectively [32,33].

Four animals were sacrificed at after 3rd, 7th, 14th, 21st and 30th day and the excised skin was withdrawn. Tissues were fixed in 10% neutral buffered formalin. Histological evaluation was performed by microscopical examination after staining with haematoxylin and eosin [34].


shear thinning, pseudo-plastic flow behavior, where there is a decrease in viscosity by increasing the shear rate (figures 1, 2).



a)




b)




c)


Figure (1): Rheogram of formula a) F1, b) F2 and c) F3.



a)



b)



c)

Figure (2): Rheogram of formula a) F4, b) F5, c) F6 .

such as molecular weight, nature of the polymer and affinity of the vehicle to bind to the drug [37].

***In-vitro* Release of Glucosamine Sulphate from different Gel Formulations:**

From the obtained data, it was observed that there was an inverse proportional relationship between the polymer concentration and the percentage of GS released (figures 3 and 4). This may be attributed to the increase in the viscosity of the formulations upon increased entangled nature of the polymeric network which is associated with the increase in polymer concentration. This is in accordance with Jones et al [35, 36].

The difference in the release of GS from the studied polymers may be due to chemical factors

It is generally recognized that if the active substance is held firmly by the vehicle, the release of the active substance is slow. As the release of the active substance generally occurred through the spaces or channels within the hydrogen network [38], it was likely that at higher polymer concentrations or increasing the polymer molecular weight, GS was more trapped in the polymer network [39]. In addition, the increase in polymer concentration could increase the density of chain structure, thereby limiting the movement area of GS [40].




Figure (3): Release Profile of GS from NaMC bases in Phosphate Buffer (pH 5.5), where F1 represents 5% Na CMC, F2 represents 5.5% Na CMC and F3 represents 6% Na CMC.




Figure (4): Release Profile of GS from PF-127 bases in Phosphate Buffer (pH 5.5), where F4 represents 15% PF-127, F5 represents 20% PF-127 and F6 represents 25% PF-127.

In-vitro permeation studies of GS through full thickness rat skin

The cumulative amount (Q) of GS penetrated into the receptor compartment per unit area ($\mu\text{g}/\text{cm}^2$) was plotted as a function of time (hours). The permeation profiles are represented in figures (5 and 6).

An inverse proportional relationship was observed between the polymer concentration and Q values of GS permeated from Na CMC gels; that was expected from the results obtained from *in-vitro* release data. The permeation data of PF-127 gels were unexpected; it was noticed that there

was an increase in Q values of GS as the polymer concentration increased (i.e direct proportional relationship).

These results may be explained depending on the non-ionic surfactant nature of PF-127 (Attwood and Florence, 1983) which increases both the solubility of drug, and their ability to bind to the stratum corneum proteins and disruption of the intercellular lipid matrix [41, 42], selective loss of intercellular lipids, and an increase in the hydration levels of the tissues as a result of more exposure of water binding sites [43].




Figure (5): Permeation profile of GS from F1, F2 and F3, where F1 represents 5% Na CMC, F2 represents 5.5% Na CMC and F3 represents 6% Na CMC.




Figure (6): Permeation profile of GS from F4, F5 and F6, where F4 represents 15% PF-127, F5 represents 20% PF-127 and F6 represents 25% PF-127.

***In-vitro* Skin Permeation Study After Addition of Permeation Enhancer:**

Several enhancement techniques have been developed to overcome the impervious nature of the stratum corneum. A popular technique is the use of the permeation enhancers, which alter reversibly the permeability barrier of the stratum corneum. DMSO has been extensively used as

permeation enhancer in the permeation of hydrophilic and lipophilic drugs [44-47].

The transport of GS through skin was increased significantly in presence of 10% DMSO this was found to be in agreement with Abdul Faruk et al [48] (Abdul Faruk et al, 2009). The permeation profiles are represented in figures (7, 8).




Figure (7): Permeation profile of GS from F1, F2 and F3 containing 10% DMSO, where F1 represents 5% Na CMC, F2 represents 5.5% Na CMC and F3 represents 6% Na CMC.




Figure (8): Permeation profile of GS from F4, F5 and F6 containing 10% DMSO, where F4 represents 15% PF-127, F5 represents 20% PF-127 and F6 represents 25% PF-127.

The percentage of permeation efficiency data was statistically analyzed using independent sample t-test at $p \leq 0.05$. It was found that PE_{24} of GS increased significantly after addition of 10% DMSO to gel formulae. The permeation efficiency (PE_{24}), which describes the whole permeation

profile (rate and extent of permeation), was calculated (table 3) and represented in figure (9). Depending on PE_{24} , F6, was found to have the highest value and was chosen for skin irritation and histological evaluation of the skin test.

Table (3): Permeation efficiency of GS from gel bases.

Formulae	In Absence of DMSO	In Presence of DMSO
F1	19.083 ± 0.020	22.238 ± 0.005
F2	14.082 ± 0.052	19.603 ± 0.064
F3	9.111 ± 0.052	13.435 ± 0.099
F4	16.960 ± 0.033	18.362 ± 0.120
F5	18.456 ± 0.012	21.000 ± 0.027
F6	21.480 ± 0.015	22.704 ± 0.005




Figure (9): *In-vitro* permeation efficiency of gel formulae after addition of 10 % DMSO.

Skin Irritation and Histological evaluation of the skin Test

Assessment of irritation of pharmaceutical and cosmetic products with natural compounds is a significant step in the evaluation of their biocompatibility. Researchers and regulatory agencies recognize the important role of *in vitro* and animal tests play in the biological evaluation of transdermal products [49].

F6 was found to produce almost no skin reactions, neither erythema nor edema, in the tested rats.

Histological examination of the excised skin under binocular light microscope showed no apparent change in the skin layers that treated with F6 when compared to control one during the whole tested period (figure 10).




Figure (10): Light microscopic photographs of rat skin; (a) control, (b) following 3 days of daily application of GS gel, (c) following 7 days of daily application of GS gel, (d) following 14 days of daily application of GS gel, (e) following 21 days of daily application of GS gel and (f) following 30 days of daily application of GS gel.

Conclusion

In conclusion, Na CMC and PF-127 were suitable bases for preparation of GS gels. On the basis of the highest drug permeation, formulation F6 was selected, which contained PF-127 (25%

w/w) in combination with (10% w/w) DMSO, for skin irritation and histological evaluation of the skin test. *In-vitro* skin irritation and histological evaluation of the skin test revealed no meaningful skin irritation or histological toxicity

manifestations. Based on the previous results it is possible to conclude that GS could be formulated safely in a stable TDS using 25% PF-127. Further studies will be warranted to assess the safety of F6 in the real clinical setting and permeation studies across human skin.

REFERENCES

1. N. Poolsup, C. Suthisisang, P. Channark, W. Kittikuluth, Glucosamine Long-Term Treatment and the Progression of Knee Osteoarthritis: Systematic Review of Randomized Controlled Trials, *The Ann. Pharm.* 39 (2005) 1080-1087.
2. P.cCreamer, Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?, *Ann. Rheum. Dis.* 56 (1997) 634-636.
3. AJ. Carr, Beyond disability: measuring the social and personal consequences of osteoarthritis, *Osteo. Cart.* 7 (1999) 230-238.
4. M. Kanwischer, S. Kim, S. Bian, Evaluation of the physicochemical stability and skin permeation of glucosamine sulphate. *Drug Dev. Ind. Pharm.* 1 (2005) 91-97.
5. B.A. Fox, E.D. Schmitz, R.Wallace, Glucosamine and Chondroitin for Osteoarthritis, *Amer. Fam. Phys. Health Module* 73 (2006) 7, 1245-1246.
6. A.A. Habashi, HPLC determination of glucosamine in rat plasma, *J. Pharm. Pharmaceut. Sci.* 5 (2002 a) 2, 176-180.
7. G. Hawker, Update on the epidemiology of the rheumatic disease, *Curr. Opin. Rheumatol.*, 9 (1997) 90-94.
8. C. Sullivan, J. Sherma, Development and validation of an HPTLC-Densitometry method for assay of glucosamine of different forms in dietary supplement tablets and capsules, *ACTA Chromatographica.* 15 (2005) 119-130.
9. H.H.Freeze, Sweet solution: sugars to the rescue, hypothesis on how glucosamine may work in treating OA, *J. of Cell Biol.*, 158 (2002) 4, 615-616.
10. G.C. De los Reyes, R.T. Koda, E.J. Lien, Glucosamine and chondroitin sulfates in the treatment of osteoarthritis, *Prog. Drug Res.*, 55 (2000) 81-103.
11. D.S Hungerford L.C. Jones, Glucosamine and chondroitin sulfate are effective in the management of osteoarthritis, *J. Arthropl.* 18 (2003), 3, suppl. 1:5-9.
12. R. Largo, Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes, *Osteo. Cart.* 11 (2003), 4, 290-298.
13. P.S. Chan, Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate, *J. Rheumatol.* 33 (2006), 7, 1329-1340.
14. C. Bassleer, L. Rovati, P. Franchimont, Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro, *Osteo. Cart.* 6 (1998) 427-434.
15. G.R. Dodge, Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes, *Osteo. Cart.* 11 (2003) 6, 424-432.
16. P.S. Chan, Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants, *Am. J. Vet. Res.*, 66 (2005) 11, 1870-1876.
17. E.J. Uitterlinden, Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants, *Osteo. Cart.* 14 (2006) 3, 250-257.
18. S.C. Chu, Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis, *Clin. Chim. Acta.* 372 (2006) 1-2, 167-172.
19. C.J. Meiningner, K.A. Kelly, H. Li, T.E. Haynes, G. Wu, Glucosamine inhibits inducible nitric oxide synthesis, *Biochem. Biophys. Res. Commun.* 279 (2000) 234-239.
20. J.Y. Reginster, R. Deroisy, L.C. Rovati, Long-term effects of glucosamine sulphate on osteoarthritis

- progression: a randomised, placebo-controlled clinical trial, Lancet, 357 (2001) 251-256.*
21. I. Setnikar, R. Pertusi, S. Canali, G. Zanolo, *Pharmacokinetics of glucosamine in man, Arzneimittel-Forschung, 43 (1993) 1109-1113.*
 22. A.A. Habashi, *Single dose, pharmacokinetics and bioavailability of glucosamine in the rat, J. Pharm. Pharmaceut. Sci., 5 (2002) 2, 181-184.*
 23. I.R. Schmolka, *Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns, J. Biomed. Mater. Res. 6 (1972) 571-582.*
 24. D.S. Jones, A.D. Woolfson, A.F. Brown, W.A. Coulter, C. Melland, C.R. Irwin, *Design, characterization and preliminary clinical evaluation of a novel mucoadhesive topical formulation containing tetracycline for the treatment of periodontal disease, J. Cont. Release. 67 (2000) 357-362.*
 25. M.A. El-Nabarawi, D.I. Nesseem A.A. Sleem, *Delivery and analgesic activity of tramadol from semi-solid (topical) and solid (rectal) dosage forms, Bull. Fac. Pharm. Cairo Univ. 41 (2003) 2, 25-31.*
 26. K. Devi, K.L.K. Paranjothy, *Pharmacokinetic profile of a new matrix type transdermal delivery system: diclofenac diethyl ammonium patch, Drug Dev. Ind. Pharm. 25 (1999) 695-700.*
 27. K.C. Sung, J. Fang, Hu OY, *Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis, J. Contr. Rel. 67 (2000) 1-8.*
 28. J. Fang, C. Hung, Y. Fang, T. Chan. *Transdermal iontophoresis of 5-fluorouracil combined with electroporation and laser treatment, Int. J. Pharm. 270 (2004) 241-249.*
 29. J. Huang, K.C. Sung, Hu OY, J. Wang, Y. Lin, J. Fang, *The effects of electrically assisted methods on transdermal delivery of nalbuphine benzoate and sebacyl dinalbuphine ester from solutions and hydrogels, Int. J. Pharm. 297 (2005) 162-171.*
 30. H. Tetsuya, K. Asako, M. Jaori, Y. Go, H. Teruki, A. Masayuki, T. Hiroaki, S. Kenji, *Analysis of skin disposition and metabolism of ethyl nicotinate after topical application using dual agar gel disc-inserted rats, Biol. Pharm. Bull., 31 (2008) 1, 85-89.*
 31. Y. Wu, M. Hussain, T. Fssihi, *Development of a simple analytical methodology for determination of glucosamine release from modified release matrix tablets, J. Pharm. Biom. Anal., 38 (2005) 263-269.*
 32. S. Iri, H. Tsukikawa, T. Nabeshima, M. Usami, T. Karino, S. Komatsu, M. Akasaki, *Skin Tests of a Novel Nicotine Patch, PHK-301p, in Healthy Male Volunteers: Phase I, Placebo-Controlled Study, J. Pharmacol. Sci. 102 (2006) 72 – 76.*
 33. R. Hayakawa, Y. Ninagawa, *Skin safety evaluation of nadifloxacin (OPC-7251) ointment, Skin Res., 42 (2000) 509-513.*
 34. C. Alemdaroglu, Z. Degim, N. Celebi, F. Zor, S. Ozturk, D. Erdogan, *An investigation on burn wound healing in rats with chitosan gel formulation containing epidermal growth factor, Burns. 32 (2006) 319-327.*
 35. D.S. Jones, A.D. Woolfson, A.F. Brown, *Textural, viscoelastic and mucoadhesive properties of pharmaceutical gels composed of cellulose polymers, Int. J. Pharm., 151 (1997) 223-233.*
 36. H.M. El laithy, K.M.F. El-Shaboury, *The Development of Cutina Lipogels and Gel Microemulsion for Topical Administration of Fluconazole, AAPS PharmSciTech., 3 (2002) 4, article 35. (<http://www.aapspharmscitech.org>)*
 37. M. Campos-Aldrete, L. Villafuerte-Robles, *Influence of the viscosity grade and the particle size of HPMC on metronidazole release from matrix tablets, Eur. J. Pharm. Biopharm., 43 (1997) 2, 173-178.*
 38. H. Shojaei, *Buccal mucosa as a route for systemic drug delivery: a review, J. Pharm. Pharm. Sci., 1 (1998) 15-30.*
 39. C. Tas, C.K. Ozkan, A. Savaser, Y. Ozkan, U. Tademir, H. Altunay, *Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in*

- vivo evaluation, *Eur. J. Pharm. Biopharm.*, 64 (2006) 246-254.
40. C. Tas, C.K. Ozkan, A. Savaser T. Baykara, In vitro release studies of chlorpheniramine maleate from gels prepared by different cellulose derivatives. *IL. Farmaco.*, 58 (2003) 605-611.
41. M.M. Breuer, The interaction between surfactants and keratinous tissues, *J. Soc. Cosm. Chem.*, 30 (1979) 41-64.
42. G. Imokawa, S. Akasaki, Y. Minemastu, M. Kawai, Importance of intercellular lipids in water-retention properties of the stratum corneum: induction and recovery study of surfactant dry skin, *Arch. Dermat. Res.*, 281 (1989) 45-51.
43. L.D. Rhein, C.R. Robbins, K. Fernee, R. Cantore, Surfactant structure effects on swelling of isolated human stratum corneum, *J. Societ. Cos. Chem* 37 (1986) 125-139.
44. S. Dey, B. Mazumder, J.R. Patel, Enhanced percutaneous permeability of acyclovir by DMSO from topical gel formulation, *Int. J. Pharm. Sci. Drug Res.* 1 (2009) 1, 13-18.
45. A. Chandar, P.K. Sharma, Transdermal delivery of ketorelac, *The Pharm. Societ. Jap.*, 129 (2009) 3, 373-379.
46. I.B. Pathan, C.M. Setty, Chemical permeation enhancers for transdermal delivery system, *Top. J. Pharmaceut. Res.* 8 (2008) 2, 173-179.
47. H.O. Ammar, M. Ghorab, S.A. El-Nahhas, R. Kamel, Evaluation of chemical penetration enhancer for transdermal delivery of aspirin, *Asian J. Pharmaceut. Sci.* 2 (2007) 3, 96-105.
48. Abdul Faruk, G. Singh, M.P.S. Ishar, Effect of drug concentration and permeation enhancer on iontophoretic transport of salbutamol sulphate *in vitro*, *Int. J. Pharm. Sci. Nanotechnology*, 1 (2009) 4, 341-348.
49. N. Kamkaen, W. Phuntuwate, W. Samee, A. Boonrod, C. Treesak, The Investigation of the Rabbit and Human Skin Irritation of Herbal Anti-wrinkle Cream, *Thai. Pharmaceut. Health Sci. J.*, 2 (2007) 1, 20-25.
